Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iva Pelosini

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Chemotherapy|April 28, 2005
Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tractIva Pelosini, Carmelo Scarpignato
Chemotherapy|April 28, 2005
Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potentialCarmelo Scarpignato, Iva Pelosini
Digestion|February 25, 2006
Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibioticCarmelo Scarpignato, Iva Pelosini
Digestive Diseases (Basel, Switzerland)|May 16, 2006
Acid suppression therapy: where do we go from here?Carmelo Scarpignato, Iva Pelosini, Francesco Di Mario
Digestion|February 25, 2006
Eradication of Helicobacter pylori: are rifaximin-based regimens effective?Antonio Gasbarrini, Giovanni Gasbarrini, Iva Pelosini, et al.
European Journal of Gastroenterology & Hepatology|September 9, 2011
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazoleFabio Pace, Bogdana Coudsy, Byron DeLemos, et al.
Advances in Therapy|February 6, 2010
New therapeutic approaches for management of sport-induced muscle strainsAngelo De Carli, Piero Volpi, Iva Pelosini, et al.
Annals of the New York Academy of Sciences|September 29, 2011
Barrett's esophagus: proton pump inhibitors and chemoprevention IIJoel E Richter, Roberto Penagini, Andrea Tenca, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Chemotherapy|April 28, 2005
Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tractIva Pelosini, Carmelo Scarpignato
Chemotherapy|April 28, 2005
Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potentialCarmelo Scarpignato, Iva Pelosini
Digestion|February 25, 2006
Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibioticCarmelo Scarpignato, Iva Pelosini
Digestive Diseases (Basel, Switzerland)|May 16, 2006
Acid suppression therapy: where do we go from here?Carmelo Scarpignato, Iva Pelosini, Francesco Di Mario
Digestion|February 25, 2006
Eradication of Helicobacter pylori: are rifaximin-based regimens effective?Antonio Gasbarrini, Giovanni Gasbarrini, Iva Pelosini, et al.
European Journal of Gastroenterology & Hepatology|September 9, 2011
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazoleFabio Pace, Bogdana Coudsy, Byron DeLemos, et al.
Advances in Therapy|February 6, 2010
New therapeutic approaches for management of sport-induced muscle strainsAngelo De Carli, Piero Volpi, Iva Pelosini, et al.
Annals of the New York Academy of Sciences|September 29, 2011
Barrett's esophagus: proton pump inhibitors and chemoprevention IIJoel E Richter, Roberto Penagini, Andrea Tenca, et al.
Pageof 1